QLGN - Qualigen Year-over-year net earnings per share growth for the last 12 months

Corporate company logo of Qualigen (QLGN)

Quarterly earnings per share growth reflects volatile market expectations, where 0.30 indicates the current level for Qualigen Therapeutics (QLGN). This price action is driven by management restructuring focused on oncology and cost optimization. Growth potential is based on the mass adoption of diagnostic systems. The stability of the R&D core and the retention of leading virologists ensure the protection of Qualigen Therapeutics (QLGN) intellectual capital during this transformation period.

Qualigen Therapeutics, Inc. (QLGN) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/19/2025

QLGN (Qualigen Therapeutics): analytical breakdowns and indicator data

- market value and analyst target forecast:
Price Chart Qualigen|QLGN - Fair Value Consensus
- market capitalization statistics:
Market Valuation Qualigen Corp|QLGN - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Qualigen Therapeutics|QLGN - Book Valuation of Business|Market Value to Book Value Ratio qualigeninc.com|QLGN - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio Qualigen Therapeutics|QLGN - Long-Term Debt to Capital|Short-Term Debt to Capital qualigeninc.com|QLGN - Company Aggregate Debts|Debt to Book Capitalization Ratio Qualigen Therapeutics|QLGN - Company Long-Term Debt|Company Short-Term Debts Qualigen Therapeutics|Quick Ratio qualigeninc.com
- earnings and market multiples details:
QLGN - Annual Net Income|Projected Future Earnings Qualigen Therapeutics|QLGN - Market Cap to Earnings|Future Price to Earnings Qualigen Therapeutics, Inc.|QLGN - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Qualigen Therapeutics, Inc.|QLGN - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Qualigen Therapeutics|QLGN - Earnings per share for the last four quarters|Quarterly EPS earnings growth qualigeninc.com|QLGN - Earnings per share increase in current year|Earnings growth forecast for next year Qualigen Therapeutics
- sales and revenue data:
QLGN - Company Total Revenue|Company Projected Revenue Qualigen|QLGN - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Qualigen Corp|QLGN - Sales Growth YoY (TTM)
Initial company analysis:Qualigen Therapeutics
Finished products of Qualigen Corp

For Qualigen Therapeutics (QLGN), which is transitioning toward the development of oncology drugs, profit dynamics are critical, as R&D costs often outpace revenue. By analyzing the growth rates of quarterly net income per share, an investor tracks the velocity of EPS changes, which allows for the timely detection of business stagnation and the avoidance of purchasing overvalued assets amid the company's liquidity shortage.

Direct competitors

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth curevac.com|Year-over-year earnings per share growth for the last twelve months Valneva Corp (VALN)|Year-over-year earnings per share growth for the last twelve months VIR (Vir Biotechnology)|Year-over-year earnings per share growth for the last twelve months TPOXX SIGA|EBS - Year-over-year net earnings per share growth for the last 12 months|AVIR: Year-over-year net earnings per share growth for the last 12 months|IVVD (Invivyd Inc) - Year-over-year earnings per share growth for the last 12 months|ENTA: Quarterly EPS earnings growth|INO (Inovio) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months HilleVax Corp|Quarterly EPS earnings growth Kalaris Tx|Quarterly EPS earnings growth DYAI|Year-over-year earnings per share growth for the last twelve months NNVC (NanoViricides)|Quarterly EPS earnings growth TLPH (Talphera Corporation)|Year-over-year net earnings per share change for the last twelve months Cocrystal (COCP)|TRAW - Year-over-year earnings per share growth for the last twelve months|DWTX (Dogwood Therapeutics Inc.) - Year-over-year earnings per share growth for the last 12 months|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)